Crisugabalin

Crisugabalin (HSK16149) is a selective GABA analog in development for the treatment of chronic pain. It has a wider therapeutic index than pregabalin, which as a similar mechanism of action. It is in Phase III trials as of 2023. The drug can be administered with or without food.